Daniel Ospina Herrera
Daniel Ospina Herrera has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Dadier Antonio Arroyo Monterroza
Clínica Centro and Faculty of Chemistry and Pharmacy Universidad del Atlántico Barranquilla Colombia
1 shared publication - Dina Rodríguez Rodríguez
Clínica Centro (CIACC)
1 shared publication - Maria Suarez Sanchez
Clínica Centro (CIACC)
1 shared publication - María Teresa Pulgar-Guariato
Clínica Centro (CIACC)
1 shared publication
Latest Publications
- Open Access
- 24 March 2026
- Published by Universidad de Cartagena in Revista Ciencias Biomédicas
- Vol. 14 (3) , 165-172
Use of aluminum sulfate in continuous bladder irrigation for the treatment of hematuria: a case series
Introduction: hematuria, defined as the presence of blood in urine, poses a therapeutic challenge when refractory to conventional treatments. Its prevalence ranges from 2.5% to 20% in adults, with 80% of cases being of urological origin. Initial management strategies include hydration, three-way Foley catheter insertion, and clot evacuation. However, in refractory cases, innovative therapeutic alternatives such as aluminum salts are warranted. Objective: to describe the outcomes of continuous bladder irrigation with aluminum sulfate solution for the treatment of hematuria through a case series. Methods: this was an observational, descriptive, and retrospective case series study conducted in a quaternary care hospital in Barranquilla, Colombia, during 2024. Ten male patients (median age: 71 years) hospitalized due to spontaneous hematuria were included. Following the failure of conservative management, continuous bladder irrigation with 1% aluminum sulfate solution (30 g in 3000 mL of sterile water) was administered at a rate of 200 mL/h. Results: complete resolution of hematuria was achieved in 100% of cases within 48–72 hours of treatment. The most frequent comorbidities were prostatic disease (90%), arterial hypertension (60%), and chronic kidney disease (60%), with bacterial colonization detected in 60% of cases. Cystoscopic findings included prostatic abnormalities (90%), bladder inflammation (20%), and lithiasis (10%), with retained clots observed in all patients. Conclusions: A 1% aluminum sulfate solution appears to be a safe and effective therapeutic option for the management of refractory hematuria. Nevertheless, prospective clinical trials are required to establish the optimal treatment protocol.
- 24 March 2026
- Published by Universidad de Cartagena in Revista Ciencias Biomédicas
- Vol. 14 (3) , 165-172
Open AccessUse of aluminum sulfate in continuous bladder irrigation for the treatment of hematuria: a case series
Introduction: hematuria, defined as the presence of blood in urine, poses a therapeutic challenge when refractory to conventional treatments. Its prevalence ranges from 2.5% to 20% in adults, with 80% of cases being of urological origin. Initial management strategies include hydration, three-way Foley catheter insertion, and clot evacuation. However, in refractory cases, innovative therapeutic alternatives such as aluminum salts are warranted. Objective: to describe the outcomes of continuous bladder irrigation with aluminum sulfate solution for the treatment of hematuria through a case series. Methods: this was an observational, descriptive, and retrospective case series study conducted in a quaternary care hospital in Barranquilla, Colombia, during 2024. Ten male patients (median age: 71 years) hospitalized due to spontaneous hematuria were included. Following the failure of conservative management, continuous bladder irrigation with 1% aluminum sulfate solution (30 g in 3000 mL of sterile water) was administered at a rate of 200 mL/h. Results: complete resolution of hematuria was achieved in 100% of cases within 48–72 hours of treatment. The most frequent comorbidities were prostatic disease (90%), arterial hypertension (60%), and chronic kidney disease (60%), with bacterial colonization detected in 60% of cases. Cystoscopic findings included prostatic abnormalities (90%), bladder inflammation (20%), and lithiasis (10%), with retained clots observed in all patients. Conclusions: A 1% aluminum sulfate solution appears to be a safe and effective therapeutic option for the management of refractory hematuria. Nevertheless, prospective clinical trials are required to establish the optimal treatment protocol.